MA29625B1 - Immunoglobulines - Google Patents

Immunoglobulines

Info

Publication number
MA29625B1
MA29625B1 MA30565A MA30565A MA29625B1 MA 29625 B1 MA29625 B1 MA 29625B1 MA 30565 A MA30565 A MA 30565A MA 30565 A MA30565 A MA 30565A MA 29625 B1 MA29625 B1 MA 29625B1
Authority
MA
Morocco
Prior art keywords
immunoglobulin
antibodies
prophylaxis
disorders
treatment
Prior art date
Application number
MA30565A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Paul Andrew Hamblin
Farhana Hussain
Alan Peter Lewis
Ruth Mcadam
Rabinder Prinjha
Paul Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513766A external-priority patent/GB0513766D0/en
Priority claimed from GB0525448A external-priority patent/GB0525448D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29625B1 publication Critical patent/MA29625B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps anti-NOGO, des formulations pharmaceutiques les contenant et l'utilisation de ces anticorps dans le traitement et/ou la prophylaxie de maladies/troubles neurologiques.
MA30565A 2005-07-05 2008-01-09 Immunoglobulines MA29625B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0513766A GB0513766D0 (en) 2005-07-05 2005-07-05 Immunoglobulins
GB0525448A GB0525448D0 (en) 2005-12-14 2005-12-14 Immunoglobulins

Publications (1)

Publication Number Publication Date
MA29625B1 true MA29625B1 (fr) 2008-07-01

Family

ID=37604821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30565A MA29625B1 (fr) 2005-07-05 2008-01-09 Immunoglobulines

Country Status (21)

Country Link
EP (1) EP1899377B1 (fr)
JP (1) JP2009500363A (fr)
KR (1) KR20080030960A (fr)
AU (1) AU2006265276B2 (fr)
BR (1) BRPI0612734A2 (fr)
CA (1) CA2614076A1 (fr)
CR (1) CR9623A (fr)
CY (1) CY1113310T1 (fr)
DK (1) DK1899377T3 (fr)
EA (1) EA014291B1 (fr)
ES (1) ES2391902T3 (fr)
HR (1) HRP20120851T1 (fr)
IL (1) IL188282A (fr)
MA (1) MA29625B1 (fr)
NO (1) NO20076663L (fr)
NZ (1) NZ564567A (fr)
PL (1) PL1899377T3 (fr)
PT (1) PT1899377E (fr)
SG (1) SG162829A1 (fr)
SI (1) SI1899377T1 (fr)
WO (1) WO2007003421A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
MX2010004831A (es) * 2007-11-02 2010-05-21 Novartis Ag Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas.
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
US10815308B2 (en) 2018-12-21 2020-10-27 Kymab Limited FIXaxFX bispecific antibody with common light chain
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
EP2213684A3 (fr) * 2003-12-22 2011-05-18 Glaxo Group Limited Anticorps nogo-a pour le traitement de la maladie d'Alzheimer

Also Published As

Publication number Publication date
KR20080030960A (ko) 2008-04-07
CR9623A (es) 2008-04-10
AU2006265276B2 (en) 2011-10-13
HRP20120851T1 (hr) 2012-11-30
ES2391902T3 (es) 2012-11-30
EP1899377A2 (fr) 2008-03-19
WO2007003421A2 (fr) 2007-01-11
JP2009500363A (ja) 2009-01-08
HK1115598A1 (en) 2008-12-05
PL1899377T3 (pl) 2013-01-31
SI1899377T1 (sl) 2012-12-31
SG162829A1 (en) 2010-07-29
WO2007003421A3 (fr) 2007-04-12
EA200702634A1 (ru) 2008-06-30
NO20076663L (no) 2008-02-27
AU2006265276A1 (en) 2007-01-11
IL188282A (en) 2011-04-28
NZ564567A (en) 2010-09-30
PT1899377E (pt) 2012-11-20
IL188282A0 (en) 2008-04-13
EP1899377B1 (fr) 2012-08-22
EA014291B1 (ru) 2010-10-29
BRPI0612734A2 (pt) 2010-11-30
DK1899377T3 (da) 2012-11-12
CA2614076A1 (fr) 2007-01-11
CY1113310T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
MA30041B1 (fr) Immunoglobulines
MA28289A1 (fr) Immunoglobulines
MA30340B1 (fr) Nouveaux composes
MA29625B1 (fr) Immunoglobulines
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA33381B1 (fr) Proteine de liaison a il-13
TNSN04268A1 (fr) UTILISATION D'INHIBITEURS CETP ET FACULTATIVEMENT D'INHIBITEURS DE HMG -CoA - REDUCTASE ET/OU D'AGENTS ANTI-HYPERTENSIFS
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP1848431A4 (fr) Formulations liquides pour le traitement de maladies ou affections
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
DE60033649D1 (de) Verbindungen und therapeutische methoden
MA33753B1 (fr) Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci